Nadofaragene Firadenovec-vncg (Adstiladrin) — CPB 1024 | AETNA Coverage Update

Aetna modified CPB 1024 for nadofaragene firadenovec-vncg (Adstiladrin), effective December 11, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its Adstiladrin coverage policy under CPB 1024 Aetna system, covering HCPCS code J9029 for nadofaragene firadenovec-vncg injection. This gene therapy targets a narrow, well-defined patient population — BCG-unresponsive, high-risk non-muscle invasive bladder cancer with carcinoma in situ — and Aetna draws hard lines around every criterion. If your practice bills J9029 for Adstiladrin, the criteria in this updated policy will determine whether you get paid or get a claim denial.

Quick-Reference Table

Aetna Adstiladrin Coverage Criteria and Medical Necessity Requirements 2025

The Aetna Adstiladrin coverage policy under CPB 1024 sets three hard criteria for initial approval. All three must be met. Not two out of three — all three. That structure is worth paying attention to, because a claim denial here means full write-off on a drug that carries a significant price tag.

Here's what Aetna requires for initial medical necessity approval:

The third criterion is the one most likely to trip up documentation. "BCG-unresponsive" has a clinical definition — it means the cancer persisted or recurred after adequate BCG therapy. Your clinical notes need to make that explicit. "Failed BCG" isn't specific enough. Document the BCG treatment history, the number of instillations, and the response assessment.

Prior authorization is mandatory. There is no path to reimbursement for J9029 without precertification. Aetna requires it for all participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 to initiate. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal.

Bill the drug itself under HCPCS J9029 — "Injection, nadofaragene firadenovec-vncg, per therapeutic dose." CPT 50720 handles the instillation procedure. Both codes need to be on your radar before the first claim goes out.

Continuation of therapy carries its own standard. Aetna covers ongoing treatment when two conditions hold: no unacceptable toxicity and no disease recurrence on the current regimen. Reauthorization requests need to address both. If there's documented progression, Aetna will not authorize continuation — that's not a gray area in this policy.

Aetna Adstiladrin Exclusions and Non-Covered Indications

Aetna's position on all other uses of nadofaragene firadenovec-vncg is flat: experimental, investigational, or unproven.

There are no carve-outs. No off-label exceptions for other bladder cancer subtypes, no coverage for muscle-invasive disease, no coverage for NMIBC without CIS. If the diagnosis doesn't map to D09.0 with all three criteria satisfied, Aetna won't pay.

This matters for practices billing a broad urology patient mix. Adstiladrin is FDA-approved specifically for high-risk, BCG-unresponsive NMIBC with CIS — and Aetna's coverage policy matches that label exactly. Any use outside those parameters is a denial waiting to happen. Don't let enthusiasm for a new therapy outrun the documentation.

Coverage Indications at a Glance

Aetna Adstiladrin Billing Guidelines and Action Items 2025

The Adstiladrin billing guidelines under CPB 1024 are tighter than most drug policies Aetna runs. This is gene therapy, and Aetna treats it accordingly. Here's what your billing team needs to do before the December 11, 2025 effective date and for every claim going forward.

If you're billing Adstiladrin for more than a handful of patients, talk to your compliance officer about how your documentation standards hold up against Aetna's three-criterion requirement. A pre-billing audit on the first few cases is worth the time.

CPT, HCPCS, and ICD-10 Codes for Nadofaragene Firadenovec-vncg Under CPB 1024

Covered HCPCS Codes (When Selection Criteria Are Met)

Other CPT and HCPCS Codes Related to CPB 1024

These codes appear in the policy as contextually related — supporting documentation of BCG treatment history or the instillation procedure itself. They are not covered codes for Adstiladrin reimbursement independently, but they're part of the broader claim picture.

Key ICD-10-CM Diagnosis Codes

D09.0 is your only covered diagnosis code under this policy. Use it. Any other bladder cancer ICD-10 code will not satisfy Aetna's criteria for J9029 reimbursement.